TNF and Bartsocas-Papas syndrome 1: A randomized, double-blind, placebo-controlled study of anti-TNFα monoclonal antibody (certolizumab pegol) treatment demonstrated significant symptom improvement in patients with IC/BPS compared with that in patients who received placebo [74].